Medindia

X

Edison Issues Initiation on Immunovia (IMMUNOV)

Thursday, November 10, 2016 Research News J E 4
Advertisement

LONDON, November 10, 2016 /PRNewswire/ --

Immunovia is ready to validate its test for the early diagnosis of pancreatic cancer from its IMMray platform. Pancreatic cancer is rare and difficult to treat, with a five-year survival rate of c 5%; early diagnosis could improve this to c 50%. This would make an accurate diagnostic test cost-effective in higher-risk patient groups. A prospective trial will start in Q416, with first out-of-pocket sales in 2018 before reimbursement is achieved. Screening of patients newly diagnosed with type 2 diabetes provides additional upside. We value Immunovia at SEK2.6bn or SEK155.2/share.

     (Logo: http://photos.prnewswire.com/prnh/20130417/608168 )

We believe there is upside to SEK155.2 per share (SEK149.6 diluted), assuming a penetration rate of 35% in high-risk patients and 5% in T2D patients, which results in targeting total peak sales of c SEK2.1bn for both groups. During September-October 2016, Immunovia raised c SEK218.6m at a price of SEK87 per share to fund a clinical trial in the T2D group. Continued business execution and expansion to further indications should unlock further value.

Click here to view the full report.

All reports published by Edison are available to download free of charge from its website http://www.edisoninvestmentresearch.com.

About Edison: Edison is an international equity research firm with a team of over 110 analysts, investment and roadshow professionals and works with both large and smaller capitalised companies, blue chip institutional investors, wealth managers, private equity and corporate finance houses to support their capital markets activity. Edison provides services to more than 420 retained corporate and investor clients from offices in London, New York, Frankfurt, Sydney and Wellington. Edison is authorised and regulated by the Financial Conduct Authority.

Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.

 

Contact details: Learn more at http://www.edisongroup.com and connect with Edison on:  

LinkedIn http://www.linkedin.com/company/edison-investment-research Twitter  http://www.twitter.com/Edison_Inv_Res YouTube  http://www.youtube.com/edisonitv Google+  https://plus.google.com/105425025202328783163/posts

For more information please contact: Juan Pedro Serrate               Edison Investment Research               +44(0)20-3681-2534

Jonas Peciulis                           Edison Investment Research                 +44(0)20-3077-5728 healthcare@edisongroup.com

SOURCE Edison Investment Research

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
China Cord Blood Corporation to Report Second Quar...
S
FSSAI Invited to Speak at the 3rd Annual 'Food Qua...